Gene · 53947
Papers2,770
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 2,770
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| New Inhibitors of β-1,4-Galactosyltransferase I Discovered by Virtual Screening. | ChemMedChem | 2025 | 39714887 | PubTator, text mining | PubMed |
| Generation of a human induced pluripotent stem cell lines (UKJi003-A) from a patient with Fabry disease and healthy donor (UKJi004-A). | Stem Cell Res | 2025 | 39701018 | PubTator, text mining | PubMed |
| Molecular dynamics as an efficient process to predict 15N chemical shift anisotropy at very high NMR magnetic fields. | Phys Chem Chem Phys | 2025 | 39688270 | PubTator, text mining | PubMed |
| Molecular Indicator for Distinguishing Multi-drug-Resistant Tuberculosis from Drug Sensitivity Tuberculosis and Potential Medications for Treatment. | Mol Biotechnol | 2025 | 39446300 | PubTator, text mining | PubMed |
| Long-term enzyme replacement therapy in Fabry patients protects against oxidative and inflammatory process. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | 39436428 | PubTator, text mining | PubMed |
| Optical Genome Mapping for Cryptic Chromosomal Rearrangements Identification in Clinical Practice. | Matern Fetal Med | 2024 | 40406069 | PubTator, text mining | PubMed |
| Complement System and Adhesion Molecule Skirmishes in Fabry Disease: Insights into Pathogenesis and Disease Mechanisms. | Int J Mol Sci | 2024 | 39596318 | PubTator, text mining | PubMed |
| Gb3 trisaccharide-bearing exosomes as a novel neutralizer for Shiga toxin type 1. | Biochem Biophys Res Commun | 2024 | 39550864 | PubTator, text mining | PubMed |
| Recent Advances in Artificial Sensory Neurons: Biological Fundamentals, Devices, Applications, and Challenges. | Nanomicro Lett | 2024 | 39537845 | PubTator, text mining | PubMed |
| Human Gb3/CD77 synthase: a glycosyltransferase at the crossroads of immunohematology, toxicology, and cancer research. | Cell Mol Biol Lett | 2024 | 39511480 | PubTator, text mining | PubMed |
| [Serological and Molecular Biological Analysis of Rare Cases of p-Blood Type]. | Zhongguo Shi Yan Xue Ye Xue Za Zhi | 2024 | 39479845 | PubTator, text mining | PubMed |
| Fabry Disease in a Female: A Unique Case Highlighting the Variability in Clinical Presentation. | Cureus | 2024 | 39473688 | PubTator, text mining | PubMed |
| Comparative pharmacokinetics and pharmacodynamics of two formulations of agalsidase beta (agalsidase Biosidus) and Fabrazyme® by intravenous infusion in healthy male volunteers. | Mol Genet Metab Rep | 2024 | 39435314 | PubTator, text mining | PubMed |
| Patient with Fabry disease undergoing cardiac surgery: a word of caution. | Indian J Thorac Cardiovasc Surg | 2024 | 39416336 | PubTator, text mining | PubMed |
| 2024 Update of the TSOC Expert Consensus of Fabry Disease. | Acta Cardiol Sin | 2024 | 39308653 | PubTator, text mining | PubMed |
| Contemporary Multimodality Imaging for Diagnosis and Management of Fabry Cardiomyopathy. | J Clin Med | 2024 | 39200913 | PubTator, text mining | PubMed |
| CRISPR/Cas9-mediated suppression of A4GALT rescues endothelial cell dysfunction in a fabry disease vasculopathy model derived from human induced pluripotent stem cells. | Atherosclerosis | 2024 | 39141976 | PubTator, text mining | PubMed |
| Inflammation, Oxidative Stress, and Endothelial Dysfunction in the Pathogenesis of Vascular Damage: Unraveling Novel Cardiovascular Risk Factors in Fabry Disease. | Int J Mol Sci | 2024 | 39125842 | PubTator, text mining | PubMed |
| Delving into human α1,4-galactosyltransferase acceptor specificity: The role of enzyme dimerization. | Biochem Biophys Res Commun | 2024 | 39111055 | PubTator, text mining | PubMed |
| [What is confirmed in the treatment of Fabry's disease?] | Inn Med (Heidelb) | 2024 | 39105759 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/53947/papers?page=6